Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Biocryst Pharmaceuticals Inc shares valued at $646,511 were sold by Barnes Alane P on Dec 01 ’25. At $7.10 per share, Barnes Alane P sold 91,004 shares. The insider’s holdings dropped to 416,152 shares worth approximately $3.27 million following the completion of this transaction.
Also, Barnes Alane P sold 50,906 shares, netting a total of over 367,216 in proceeds. Following the sale of shares at $7.21 each, the insider now holds 365,246 shares.
Before that, Barnes Alane P had sold 19,770 shares from its account. In a trade valued at $151,240, the Chief Legal Officer traded Biocryst Pharmaceuticals Inc shares for $7.65 each. Upon closing the transaction, the insider’s holdings decreased to 19,770 shares, worth approximately $2.71 million.
Analysts at Evercore ISI downgraded the stock from ‘”an Outperform”‘ to ‘”an In-line”‘ outlook in a report released in early October. As of April 29, 2025, Cantor Fitzgerald has initiated its “an Overweight” rating for BCRX. Earlier on February 25, 2025, Wedbush initiated its rating. Their recommendation was “an Outperform” for BCRX stock.
Analyzing BCRX Stock Performance
On last trading session, Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] rose 9.64% to $7.85. The stock’s lowest price that day was $7.11, but it reached a high of $7.88 in the same session. During the last five days, there has been a surge of approximately 14.60%. Over the course of the year, Biocryst Pharmaceuticals Inc shares have jumped approximately 4.67%. Shares of the company reached a 52-week high of $11.31 on 06/04/25 and a 52-week low of $6.00 on 10/14/25.
Support And Resistance Levels for Biocryst Pharmaceuticals Inc (BCRX)
According to the 24-hour chart, there is a support level at 7.35, which, if violated, would cause prices to drop to 6.84. In the upper region, resistance lies at 8.12. The next price resistance is at 8.38. RSI (Relative Strength Index) is 67.86 on the 14-day chart, showing neutral technical sentiment.
Is Biocryst Pharmaceuticals Inc subject to short interest?
Stocks of Biocryst Pharmaceuticals Inc saw a sharp rise in short interest on 2025-11-14 jumping by 5.69 million shares to 36.46 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 30.77 million shares. A jump of 15.6% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.01 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.01.
Which companies own the most shares of Biocryst Pharmaceuticals Inc (BCRX)?
In terms of Biocryst Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 15 in the next 12 months, up nearly 109.5% from the previous closing price of $7.16. Analysts anticipate Biocryst Pharmaceuticals Inc stock to reach 25 by 2025, with the lowest price target being 8. In spite of this, 13 analysts ranked Biocryst Pharmaceuticals Inc stock as Buy at the end of 2025. On November 20, 2023, JP Morgan assigned a price target of “an Overweight” to the stock and resumed coverage with a $10.
